Kenneth H Jung

Title: Kenneth H Jung: Innovator in Epidermal Growth Factor Receptor Binding Agents

Introduction

Kenneth H Jung is a notable inventor based in Newbury Park, CA (US). He has made significant contributions to the field of biomedical research, particularly in the development of epidermal growth factor receptor (EGFr) binding agents. With a total of 2 patents, his work has the potential to impact therapeutic strategies in cancer treatment.

Latest Patents

Kenneth's latest patents focus on methods of selecting EGFr binding agents. The first patent describes methods that involve selecting agents that bind to at least a portion of a panitumumab epitope on an EGFr. Additionally, it outlines embodiments where the binding agents do not interact with a panitumumab epitope on an EGFr. This innovative approach could lead to more effective treatments for patients.

Career Highlights

Kenneth is currently employed at Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to collaborate with other talented professionals in the field. His contributions to the company and the industry at large are noteworthy.

Collaborations

Some of Kenneth's coworkers include Daniel Freeman and Jilin Sun. Their collaborative efforts contribute to the advancement of research and innovation in the field of EGFr binding agents.

Conclusion

Kenneth H Jung is a distinguished inventor whose work in the area of epidermal growth factor receptor binding agents showcases his commitment to advancing medical science. His patents and collaborations reflect his significant role in the biotechnology industry.